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Abstract 
            Microvolt T-wave alternans (MTWA), the beat-to-beat fluctuation in T wave amplitude 
and morphology, is closely linked to vulnerability to ventricular arrhythmias in various 
experimental and clinical conditions. Clinically, MTWA is most commonly measured using the 
spectral   method,   although   non-spectral   methods   for   its   assessment   from   ambulatory 
electrocardiographical recordings also have been developed. Recent studies suggest that the 
quantitative assessment of TWA may also be clinically relevant. The standardisation of the 
criteria for abnormal MTWA test still needs to be completed. The expansion of indications for 
implantable   cardioverter-defibrillator   (ICD)   therapy  following  the  positive  results   of   the 
MADIT-II and SCD-HeFT trials might have unacceptable economic and medical consequences, 
and therefore new tests are needed to better discriminate patients who will and will not benefit 
from ICD implantation. A recent meta-analysis of  MTWA studies revealed an overall positive 
predictive value for arrhythmic events of 19.3%, negative predictive value of 97.2%, and 3.77% 
univariate relative risk of arrhythmic events. The negative predictive value of MTWA in 
MADIT-II type patients has been reported to be 97.5%. The predictive value of the test varied 
significantly in different patient population. Current data support the use of MTWA testing for 
evaluation of patients with low ejection fraction who are considered for ICD implantation. The 
independence of the prognostic value of MTWA from other clinical and electrophysiological 
variables needs further confirmation.
Key Words:  microvolt T wave alternans, implantable cardioverter-defibrillator, ventricular 
arrhythmias, sudden cardiac death, risk stratification
Introduction
            Microvolt T-wave alternans (MTWA) represents the phenomenon of alteration in the 
shape and/or amplitude of the T wave on an every other beat basis in the microvolt (invisible to 
the naked eye) range. MTWA predisposes towards malignant ventricular tachyarrhythmias in 
various experimental conditions and clinical disorders and therefore has become in recent years 
a widely discussed noninvasive index, which can serve as a predictor of sudden cardiac death 
(SCD)1. During the last years, substantial progress has been made in understanding the cellular 
mechanism of MTWA, refining the methods of its testing and, most importantly, determining its 
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clinical value. Recent studies have provided strong indication that MTWA may be very useful 
for identifying patients who will and especially those will not benefit from implantable 
cardioverter-defibrillator (ICD) therapy among all ischaemic heart disease (IHD) patients with 
low ejection fraction (EF) ("MADIT II-like" patients), thus solving the "The MADIT II 
Conundrum"2.
            This review concentrates mainly on the most important basic and clinical studies on 
MTWA published since 2003; those published earlier have been summarised in a previous 
article3.
Basic Research on MTWA                                                                                   
               While  it  is  already  firmly  established  that  MTWA   arises  from  alternation  of 
repolarisation at the level of the single myocyte4, the exact cellular mechanism of MTWA is not 
yet completely clear. The two main hypotheses (which are not mutually exclusive) are that 
MTWA develops, a) when the myocyte cannot handle intracellular Ca2+ during each cardiac 
cycle, and b) when the slope of the action potential duration (APD) restitution curve is > 1, as 
determined by the kinetics of the cell membrane currents4. Pruvot et al.5 used high-resolution 
optical mapping techniques to measure action potentials and Ca2+ transients simultaneously from 
hundreds of epicardial sites in the guinea pig model of pacing-induced TWA. They found that 
APD and Ca2+ alternans were remarkably similar both spatially and temporally and consistently 
occurred together near the base of the left ventricle, and not where APD restitution was steepest. 
They concluded that the mechanism of TWA in the intact heart is more closely associated with 
intracellular Ca2+ cycling rather than APD restitution5.                                         
            T wave alternans, which arises as a single cell phenomenon, is not evenly distributed 
throughout the heart and its magnitude and phase can differ substantially between neighbouring 
areas (discordant alternans)4. Spatially discordant alternans provides a substrate for reentrant 
ventricular  tachyarrhythmias4.                                                                                  
            MTWA is critically related to changes in heart rate. In 2000 Narayan and Smith6 reported 
that MTWA was significantly greater and differently distributed within the JT-segment during 
heart rate deceleration compared to the same heart rates during acceleration (from 100 to 150 
beats per minute) induced by atrial and ventricular pacing during electrophysiological (EP) 
study. The phenomenon was called TWA hysteresis, similarly to the well-known hysteresis of 
the QT interval following abrupt heart rate changes7. In this study6 the time course of alternans 
hysteresis and the distribution of alternans within the JT segment were distinctly different 
between patient with and without inducible arrhythmias. The sensitivity and specificity of 
alternans for arrhythmia inducibility varied asymmetrically during heart rate acceleration and 
deceleration, which has important implications for the clinical utility of the test for risk 
stratification.  
            Other authors have used the term "alternans memory" instead of "hysteresis"4, although 
this   can   create   confusion   with   the   fundamental   concept   of   "cardiac   memory".
               In a study with isolated guinea pig ventricular myocytes and Langendorff-perfused 
guinea pig whole hearts, Walker et al.8 also demonstrated that alternans persisted at heart rates 
below those that were required to induce it. Their results showed that TWA was an intrinsic 
property of cardiac myocytes and suggested an important underlying role of calcium cycling in 
the mechanism of alternans. Moreover, they demonstrated that the hysteresis effect was stronger 
for the more arrhythmogenic form of TWA, namely discordant alternans, than for the less 
arrhythmogenic concordant TWA8.                                                                                       
            The hysteresis demonstrates that MTWA (and hence, repolarisation dispersion) depends 
not only on the heart rate, but also on the direction of change of heart rate (the "heart rate 
history"). The persistence of MTWA at slower heart rates preceded by transient heart rate 
perturbations provides a possible explanation for the occurrence of ventricular arrhythmias and 
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SCD at heart rates lower than those necessary to elicit MTWA during clinical testing8.  
               Bernus et al.9  demonstrated in a computer model of acute regional ischemia that 
ischaemia-related arrhythmias were triggered by calcium-mediated alternating conduction blocks 
in the ischaemic border zone, which led to intramural reentry and APD alternans. In an 
experimental model with endocardial and epicardial electrograms recorded in dogs during left 
anterior coronary artery occlusion and right atrial pacing, Nearing and Verrier observed orderly 
stepwise progression of the complexity of T wave oscillations (e.g. ABC-ABC or ABCD-ABCD 
patterns, more complex patterns, etc.), discordant alternans and subsequently progression to 
VF10. This study demonstrated for the first time mechanistic link underlying the ability of TWA 
to predict malignant arrhythmias.
            The relation between MTWA and cardiac sympathetic nervous system abnormality was 
recently documented with the help of Iodine-123 (I-123) metaiodobenzylguanidine (MIBG) 
myocardial imaging. In patients with idiopathic cardiomyopathy, MIBG imaging revealed defect 
areas of sympathetic denervation. In this study, a relation was found between MIBG indices 
reflecting sympathethic denervation and shifted sympathetic tone11. Using MIBG imaging, it has 
been demonstrated that in patients with non-ischemic cardiomyopathy improvement of EF after 
long term beta-blockers therapy correlated with improvement in cardiac sympathetic innervation 
and was associated with decrease in the number   of patients with positive MTWA and the 
decrease   of   MTWA   voltage12.                                                            
Development of the Methodology              
            There are several methods for measurement of MTWA (for comprehensive reviews 
see13,14). The most commonly used is the spectral method, whose principles are described in 
detail elsewhere1,3. To achieve the necessary increase in heart rate, early studies used invasive 
atrial pacing, whereas nowadays noninvasive exercise stress test with bicycle or treadmill is 
mainly used. It has been shown that the two methods provide equivalent results15. Recently a 
method for measurement of MTWA from ambulatory ECG (Holter) recordings has been 
developed. The rationale is to investigate the presence of MTWA in periods when the 
occurrence of SCD is the most frequent, that is, at peak heart rate, early morning and during 
peak ST-elevation1,14. Since the spectral analytical method requires stationary data, which 
cannot be acquired with ambulatory ECG monitoring, TWA from Holter recordings is analysed 
using a non-spectral technique, called the (Modified Moving Average Beat Analysis, MMA) 
(detailed description of the method can be found in14). Verrier et al.16  analysed the Holter 
database of the Autonomic Tone and Reflexes after Myocardial Infarction (ATRAMI) study17 
and demonstrated for the first time the value of MTWA acquired from ambulatory ECG 
recordings for risk stratification for SCD. The value of MMA methods needs to be further tested 
in prospective studies14. According to the statement of Centers for Medicare and Medical 
Services released in March 200618, "Microvolt T-wave Alternans diagnostic testing is covered 
for the evaluation of patients at risk for SCD, only when the spectral analysis method is used."   . 
           The original definitions and classification criteria of the spectral analysis of MTWA were 
strictly established13:
The test is considered positive if it has sustained alternans with an onset heart rate ≤110 
beats/min. or has sustained alternans at the resting heart rate, even if the latter is >110 
beats/min. Sustained alternans is defined as lasting at least 1 minute with alternans 
voltage (Valt) ≥1.9 μV and alternans ratio≥3 (the ratio of the alternans power divided by 
the standard deviation of the noise in the reference frequency band, a measure of the 
statistical significance of the alternans), in any of the vector leads X, Y, Z, or VM (the 
vector magnitude), or in a precordial lead  and  confirmed (with  Valt )  ≥ 1.9  μV)  in   an 
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adjacent precordial lead, with some period of artifact free-data (defined as ectopic or 
premature  beats  ≤10%  of  all  beats,  no  respiratory  activity  at  0.25  cycles  per  beat, 
variation in instantaneous heart rate <30 beats/min and no RR interval alternans present 
≥2 msec with alternans ratio≥3). 
The MTWA test is negative if 1) it does not meet criteria for being positive and 2) 
maximum negative heart rate is ≥105 beats/min. The maximum negative heart rate is the 
highest interval heart rate associated with an interval without significant alternans, with 
noise   level   in   the   vector   magnitude   lead   ≤1.8   µV,   with   ≤10%   ectopic   beats. 
The test is indeterminate if it can not be definitively classified as positive and negative. 
In recent studies, indeterminate test result, which occurs in 9-47% of the results13, is 
grouped together with positive test as "abnormal MTWA", as opposed to negative test. 
This seems appropriate only if indeterminacy reflects ectopy, rather than ECG noise1,13. 
            An example of negative MTWA taken from ischaemic patient before ICD impalantation 
because of secondary prevention without arrhythmic events during 1 year follow-up using 
Cambridge Heart, Bedford, Massachusetts is presented in Figure 1.
Figure 1.  An example of negative microvolt TWA recorded before ICD implantation in 
ischaemic patient with history of cardiac arrest due to sustained ventricular tachycardia. No 
ventricular arrhythmic events were documented during 1 year following implantation.
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            Figure 2 presents a positive test recorded in a patient with ischaemic cardiomyopathy 
before ICD implantation due to secondary prevention, who received during the third month of 
follow-up appropriate shocks because of ventricular fibrillation and sustained ventricular 
tachycardia (both examples are from our database). 
                   
Figure 2. An example of positive microvolt TWA recorded before ICD implantation in a patient 
with ischaemic cardiomyopathy and history of sustained ventricular tachycardia. The patient 
suffered several episodes of VT/VF during the third month following implantation.
            Recently it has been suggested that quantitative assessment of MTWA may provide 
independent information. Klingenheben et al.19  reported that MTWA had higher magnitude 
(Valt) and was positive in more ECG leads in cardiomyopathy patients with compared to those 
without tachyarrhythmias and in patients with non-ischaemic than in those with ischaemic 
cardiomyopathy. The authors suggested that more extensive MTWA might reflect more 
extensive myocardial damage and higher arrhythmia propensity19.   
            Currently it is accepted to keep beta-blocker agents during TWA testing14. It has been 
documented that beta-blockade diminishes the amplitude of MTWA. Therefore in order to assess 
the risk of the patient for SCD it is reasonable to continue current medications during the test21
            In a recent substudy of the Cardiac Arrhythmias and Risk Stratification after Myocardial 
Infarction (CARISMA) trial22, three methods of TWA assessment were compared: exercise 
testing, atrial pacing and simultaneous ventricular and atrial pacing23. The authors found 79% 
concordance between exercise and atrial pacing and 95% between the two pacing mode. 
Indeterminate alternans was present in 7% during ventricular and atrial pacing and in 24% 
during exercise. The high concordance between the tests and the low number of indeterminate 
tests indicate that the ventricular and atrial pacing method can be useful in TWA evaluation in 
patients who are not able to complete exercise test23.                                                     
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TWA in clinical practice: meta-analysis, era of MADIT-II and SCD-HeFT populations and 
dilated   cardiomyopathy                                                            
            There is already overwhelming evidence that treatment with ICD significantly reduces 
mortality in patients with ischaemic heart disease with reduced left ventricular EF. The second 
Multicenter   Automatic   Defibrillation   Trial   (MADIT-II)   demonstrated   28%   reduction   of 
mortality rates (absolute mortality reduction of 5.6%) during an average follow-up of 20 months 
in post-myocardial infarction (MI) patients with EF≤30% in whom ICD was implanted 
compared to those who received only conventional therapy24. In the Sudden Cardiac Death in 
Heart Failure Trial (SCD-HeFT), which enrolled patients with heart failure of ischaemic or 
nonischaemic origin in New York Heart Association (NYHA) class II or III and EF≤35% with a 
mean followed up of 45.5 months, amiodarone did not improve survival, while single-lead 
shocked ICD therapy reduced overall mortality by 23%25. It is economically unrealistic and 
ethically questionable to expect all MADIT II-like patients to receive ICD therapy, given the 
size of this population (55,000 to 65,000 new cases annually in the U.S.A.26) and the fact that the 
majority of these patients will never need the device. Therefore it is mandatory to find methods 
to differentiate patients who really need ICD implantation among all MADIT II-like patients27,28. 
Moreover, consensus panels accepted the scientific validilty of MADIT-II, but recognized the 
need for better methods of risk stratification29. In this context the recent interest in research, 
assessment   and   clinical   studies   in   T-wave   alternans   is   reasonable   and   justified.
            In 2005, Gehi et al. reported a meta-analysis of MTWA studies to clarify the predictive 
accuracy and practical usefulness of the test30. The analysis included 19 prospective studies with 
a total of 2,608 patients published between January 1900 and December 2004. The average 
follow-up was 21 months. The population included wide range of subjects: patients with 
congestive heart failure (CHF), ischemic CHF, non-ischemic, post-MI, athletes and healthy 
subjects. In the analysis indeterminate MTWA tests were excluded. The arrhythmic event was 
classified as SCD, cardiac death, VT, VF, or ICD shocks. Summary positive predictive value 
(PPV) of MTWA for arrhythmic events was 19.3% (95% confidence interval [CI] 17.7% to 
21.0%), negative predictive value (NPV) was 97.2% (95% CI 96.5% to 97.9%), and the 
univariate relative risk (RR) was 3.77 (95% CI 2.39 to 5.95). In patients with arrhythmic history, 
PPV and NPV were 51.0% and 86.0%, respectively, whereas in those without arrhythmic history 
they were 15.4% and 98.1%, respectively. There were no differences in PPV, NPV and RR 
between ischemic and non-ischemic CHF patients, but PPV was higher in CHF patients than in 
post-MI patients. In 8 studies indeterminate MTWA was included in the definition of abnormal 
test. Comparison of the results with and without inclusion of indeterminate test in these studies 
showed no significant differences in the predictive value of an abnormal test. In 3 studies, in 
which multivariate analysis was performed including MTWA and other tests, such as EF, left 
ventricular systolic diameter, NSVT, signal-average electrocardiogram and QT dispersion, 
MTWA was independently predictive of arrhythmic events3. Whilst the 97% NPV confirmed 
that a negative MTWA test can identify patients at low-risk for arrhythmic events (24-54% of 
the subjects in this analysis), in the decision who should receive an ICD for primary prophylaxis 
the 19% PPV for arrhythmic events is more relevant. The PPV of MTWA varied (from 0% to 
51%) depending on the clinical characteristic of tested patients and the pretest probability for 
arrhythmic events. This meta-analysis also revealed  the  need  for standardisation of  the 
assessment of the results of MTWA. It seems fundamentally erroneous to define as "abnormal" a 
test, which is indeterminate because of excessive noise that makes the record uninterpretable30. 
Further prospective studies are needed to define the independent predictive value or MTWA for 
cardiac  arrhythmias  in  multivariate  analysis  including  many  demographical,  clinical  and 
electrophysiological variables. In addition, future MTWA trials should provide analysis of all-
cause (in addition to arrhythmic) mortality, and should evaluate the mortality reduction benefit 
of implantable cardioverter-defibrillators (ICDs) in patients who test MTWA-negative and non- 
negative31.
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            Four recently published major studies assessed MTWA in MADIT-II like patients, and 
patients with EF≤35% or ≤40%. In the first one, included in the meta-analysis, in 129 patients 
who met MADIT-II criteria, Hohnloser et al. reported no cardiac death or cardiac arrest during 2 
years of follow-up in patients with normal TWA, compared to 15.6% among patients with 
abnormal   test32.                                                            
            In the next, more recent study, also included in the meta-analysis, on 177 MADIT-II like 
patients, Bloomfield et al. used MTWA and QRS duration to identify groups at high and low 
risk of the all-cause mortality (primary end point) during a follow-up of 2 years2. Abnormal 
(positive and indeterminate) MTWA was found in 68% patients, whereas 32% had QRS>120 
ms. The 2-year actuarial mortality rate for patients with abnormal MTWA was significantly 
greater (17.8%) than in patients with normal MTWA (3.8%, p=0.02, hazard ratio 4.8). It was 
also significantly lower in patients with normal MTWA test compared to those with narrow QRS 
(3.8%, 95% CI: 0-9.0 vs 12.0%, 95% CI: 5.6-18.5). The corresponding false-negative rates were 
of 3.5% and 10.2%, respectively. The authors concluded that in MADIT-II like population, 
abnormal MTWA was a strong predictor of all-cause mortality and identified better that QRS 
duration   patients   who   were   not   likely   to   benefit   from   ICD   therapy2.                  
            In a more recent report, the same authors extended their initial findings in analysis of 587 
patients (half with ischemic heart disease) with EF≤40%. Of them, 66% patients had an 
abnormal MTWA test. The mean follow-up was 20±6 months and primary end point was death 
and non-fatal sustained ventricular arrhythmia. The 2-year actuarial event rate was 15.0% in 
patients with abnormal MTWA test and 2.5% in those with normal (RR 6.5; 95% CI 2.4 to 
18.1). Survival of patients with normal MTWA test was 97.5%33.                             
            Recently, Chow et al.27 reported the results of a study on 768 patients with ischaemic 
cardiomyopathy, EF≤35% and no arrhythmia history. All patients underwent baseline MTWA 
test which was classified as negative and non-negative and were followed-up for an average of 
18±10 months. After multivariable adjustment, a non-negative MTWA test was associated with 
a significantly higher risk for all-cause (hazard ratio 2.24 (95% CI: 1.34 to 3.75), p=0.002) and 
arrhythmic mortality (hazard ratio 2.29 (1.00 to 5.24), p=0.049).  In subgroup analyses, a non-
negative MTWA test was also associated with a higher risk for all-cause mortality in patients 
with EF≤30% (hazard ratio 2.10 (1.18 to 3.73), p=0.01) and after excluding those with 
indeterminate MTWA tests (hazard ratio 2.08 (1.18 to 3.66), p=0.01)27.                         
            The conclusions from the above 4 studies are similar: MTWA testing not only identifies 
ischemic patients at high risk of arrhythmias, but also those who are not likely to benefit from 
ICD therapy27,32,33. In the MADIT-II trial, 18 ICDs had to be implanted to save one life. ICD 
therapy diminishes the quality of life or even can be proarrhythmic34. Based on the MADIT-II 
data, incremental cost-effectiveness ratio (iCER) was 235,000$ per year-of-life saved, and in 
perspective of 12 years this ratio ranged from 78,600 to 114,000$26. High cost, lack of enough 
hospital and physician resources or the perception that current criteria are too broad limit the 
access to the ICD for many candidates for this therapy28. For these reasons MTWA may be 
useful as a screening test to identify patients who will not benefit from ICD implantation2. 
Applying this strategy to a MADIT-II likely population, only 7 ICDs would have to be 
implanted to save 1 life32. It has been proposed that if the decision not to implant an ICD would 
be taken on the basis of a negative MTWA test, it would seem reasonable to repeat the test every 
1-2 years, since most prospective studies had follow-up between 1 and 2 years35.               
            The ongoing Microvolt T Wave Alternans Testing for Risk Stratification of Post MI 
Patients (MASTER I) trial36 is expected to provide new information about the usefulness of 
MTWA   for   the   risk-stratification   of   MADIT-II   like   patients.                              
             MTWA seems to be a promising risk factor for prediction of arrhythmic events in 
idiopathic dilated cardiomyopathy (DCM). In one observational prospective study, 137 patients 
with DCM underwent risk stratification using MTWA, EF, baroreflex sensitivity (BRS), heart 
rate variability, presence  of  nonsustained  ventricular  tachycardia  (VT),  signal-averaged 
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electrocardiogram and presence of intraventricular conduction defect37. MTWA and BRS were 
significant   univariate   predictors   of   sudden   death,   resuscitated   VF,   or   documented 
hemodynamically unstable VT during an average follow-up of 14±6 months, whereas in 
multivariate analysis only MTWA was a significant predictor. These results were supported by 2 
more studies, one of them on patients with congestive heart failure NYHA class II38, and the 
other on patients in NYHA class III39. In the former study which enrolled 81 patients, the NPV 
and PPV of TWA for SCD, documented sustained VT/VF, or appropriate ICD shock were 100% 
and 24%, respectively38. The latter study enrolled 46 patients, of whom 7 patients (16%) died 
from cardiac death (non-sudden in six and sudden in one) during the follow-up of 1.6 years. 
MTWA was positive in 24 (52%), negative in 13 (28%) and indeterminate in 9 patients (20%). 
MTWA was positive in all patients with events (100%), but only in 16 of 37 patients without 
events (41%) (p=0.02)39. On the other hand, in the Marburg Cardiomyopathy Study, which 
enrolled 343 patients with idiopathic DCM followed-up for 52±21 months, MTWA was not 
independently predictive for major arrhythmic events (46 patients, 13%) in multivariate analysis 
including reduced EF, lack of beta-blockers therapy, signal-averaged ECG, BRS, heart rate 
variability40.
            The ongoing T-wave Alternans in Patients with Heart Failure (ALPHA) trial is designed 
to evaluate the independent predictive value of MTWA on the combined occurrence of cardiac 
death and life-threatening arrhythmias, in a population of patients with non-ischemic dilated 
cardiomyopathy given NYHA class II and III, over 12-24 months follow-up41.               
MTWA   in   other   diseases   and   populations                                              
            Molon et al. performed MTWA testing in patients with type 2 diabetes mellitus42 and 
reported that the test was positive in 21% of diabetic patients without any cardiac disease. 
MTWA positive patients had significantly higher HbA1c levels than those with negative 
MTWA. The authors concluded that positive MTWA is correlated with glycaemic control42.
            Kirchof et al. performed MTWA test at rest and during exercise in nine symptomatic, 
inducible patients with established Brugada syndrome and in seven healthy controls43.  They 
concluded that MTWA cannot detect arrhythmia propensity in patients with is not appropriate in 
Brugada   syndrome.                                                      
        Furlanello et al.44 followed up 100 competitive athletes (including 72 elite), 48 of them 
normal and 52 with severe arrhythmias, for 36.1 months. They reported that positive MTWA 
was connected with symptomatic arrhythmias. During electrophysiological study, sustained 
monomorphic VT was induced in 72% of patients with positive MTWA. The authors concluded 
that MTWA seems to be useful in the assessment the risk of arrhythmic events in athletes. 
            Narayan et al.45 studied 28 patients with coronary artery disease, systolic dysfunction and 
nonsustained VT. They found that TWA magnitude, which was computed spectrally during 
ventricular stimulation, varied linearly with LV mass index (p=0.003). In addition, positive 
TWA (magnitude ≥1.9 μV) in the orthogonal electrocardiographic axes overlaid scar or wall 
motion abnormalities in corresponding echocardiographic segments (p<0.05), which suggests 
that TWA may indicate arrhythmic contributions from regional myocardial scar and eccentric 
LV   hypertrophy.                                                
Conclusions
            MTWA is a non-invasive index which is strongly correlated with arrhythmic events. Due 
to its very high negative predictive value, MTWA is especially useful as a screening method for 
identifying patients with low ejection fraction at low risk for arrhythmic events who are very 
unlikely to benefit from ICD implantation. The interpretation of the test with regard to "normal" 
and "abnormal" test still needs to be standardised. Quantitative methods of MTWA assessment 
seem promising and need further investigations.
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